Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
Authors
Keywords
-
Journal
Cancers
Volume 3, Issue 3, Pages 3114-3142
Publisher
MDPI AG
Online
2011-08-06
DOI
10.3390/cancers3033114
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
- (2012) Tim F Greten et al. BMC CANCER
- Secondary malignancies among nonseminomatous germ cell tumor cancer survivors
- (2011) Karim Chamie et al. CANCER
- Improving cancer immunotherapy by targeting tumor-induced immune suppression
- (2011) Trina J. Stewart et al. CANCER AND METASTASIS REVIEWS
- Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients
- (2011) J. A. Kyte et al. CLINICAL CANCER RESEARCH
- Myeloid cell population dynamics in healthy and tumor-bearing mice
- (2011) Satoshi Ueha et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer
- (2011) Ninke Leffers et al. INTERNATIONAL JOURNAL OF CANCER
- Safety of BLP25 Liposome Vaccine (L-BLP25) in Japanese Patients with Unresectable Stage III NSCLC after Primary Chemoradiotherapy: Preliminary Results from a Phase I/II Study
- (2011) F. Ohyanagi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine
- (2011) Craig L. Slingluff et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolution of platinum resistance in high-grade serous ovarian cancer
- (2011) Susanna L Cooke et al. LANCET ONCOLOGY
- Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens
- (2011) Lars Boeckmann et al. MELANOMA RESEARCH
- Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties
- (2011) Jennifer C. Rodrigues et al. NEURO-ONCOLOGY
- Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
- (2011) Antonella Sistigu et al. Seminars in Immunopathology
- Increased Programmed Death-1 Expression on CD4+ T Cells in Cutaneous T-Cell Lymphoma
- (2010) Sara Samimi et al. ARCHIVES OF DERMATOLOGY
- Survivin and IAP proteins in cell-death mechanisms
- (2010) Dario C. Altieri BIOCHEMICAL JOURNAL
- Differential effects of Paclitaxel on dendritic cell function
- (2010) Justin John et al. BMC IMMUNOLOGY
- A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients
- (2010) W J Lesterhuis et al. BRITISH JOURNAL OF CANCER
- Understanding the cancer stem cell
- (2010) S Bomken et al. BRITISH JOURNAL OF CANCER
- A phase 2 pilot trial of low-dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma
- (2010) Rupal S. Bhatt et al. CANCER
- Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer
- (2010) Rupal Ramakrishnan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer
- (2010) Masanori Noguchi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy
- (2010) David Coe et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
- (2010) Suzanne Ostrand-Rosenberg CANCER IMMUNOLOGY IMMUNOTHERAPY
- Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A-Specific, Tumor-Reactive CTL in Melanoma Patients
- (2010) B. Palermo et al. CANCER RESEARCH
- Selective Depletion of CD4+CD25+Foxp3+Regulatory T Cells by Low-Dose Cyclophosphamide Is Explained by Reduced Intracellular ATP Levels
- (2010) Jie Zhao et al. CANCER RESEARCH
- Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma
- (2010) K. Klages et al. CANCER RESEARCH
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
- (2010) K. Movahedi et al. CANCER RESEARCH
- Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth
- (2010) M. W. L. Teng et al. CANCER RESEARCH
- Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
- (2010) Lukas W. Pfannenstiel et al. CELLULAR IMMUNOLOGY
- Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses
- (2010) L.-Y. Kong et al. CLINICAL CANCER RESEARCH
- Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
- (2010) J. Mitsui et al. CLINICAL CANCER RESEARCH
- Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
- (2010) J. F. M. Jacobs et al. CLINICAL CANCER RESEARCH
- Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC)
- (2010) Pierpaolo Correale et al. EUROPEAN JOURNAL OF CANCER
- Personalized cancer vaccines
- (2010) Kewal K Jain EXPERT OPINION ON BIOLOGICAL THERAPY
- Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model
- (2010) Xiang Huang et al. INTERNATIONAL JOURNAL OF CANCER
- Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells
- (2010) Lorna Rettig et al. INTERNATIONAL JOURNAL OF CANCER
- Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy
- (2010) Angiolo Gadducci et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
- (2010) Rupal Ramakrishnan et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer
- (2010) Andreas du Bois et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells
- (2010) S. Nagaraj et al. JOURNAL OF IMMUNOLOGY
- Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells
- (2010) Takashi Inozume et al. JOURNAL OF IMMUNOTHERAPY
- Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
- (2010) Sara M. Mangsbo et al. JOURNAL OF IMMUNOTHERAPY
- Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer
- (2010) Miho Kaida et al. JOURNAL OF IMMUNOTHERAPY
- A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
- (2010) Rodryg Ramlau et al. Journal of Thoracic Oncology
- Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402
- (2010) Toshiyuki Baba et al. Journal of Translational Medicine
- Regulatory natural killer cells in murine liver and their immunosuppressive capacity
- (2010) Osamu Yoshida et al. LIVER INTERNATIONAL
- Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis
- (2010) Chi-An Chen et al. MOLECULAR THERAPY
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
- (2010) J. H. Sampson et al. NEURO-ONCOLOGY
- Treating Cancer by Targeting the Immune System
- (2010) Patrick Hwu NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
- (2010) Adam D. Cohen et al. PLoS One
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab
- (2010) Antoni Ribas SEMINARS IN ONCOLOGY
- Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade
- (2010) Jeffrey Weber SEMINARS IN ONCOLOGY
- CTLA-4 blockade: therapeutic potential in cancer treatments
- (2010) Ahmad Tarhini OncoTargets and Therapy
- Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells
- (2009) Andrew J. Rech et al. Annals of the New York Academy of Sciences
- Tumors induce the formation of suppressor endothelial cells in vivo
- (2009) Jennifer Konopa Mulligan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy
- (2009) Xia Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma
- (2009) Miki Tongu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Low-Dose Metronomic Paclitaxel Chemotherapy Suppresses Breast Tumors and Metastases in Mice
- (2009) Hongchi Jiang et al. CANCER INVESTIGATION
- Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer
- (2009) P.-Y. Pan et al. CANCER RESEARCH
- Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
- (2009) S. Wada et al. CANCER RESEARCH
- Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
- (2009) M. K. Srivastava et al. CANCER RESEARCH
- Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies
- (2009) M. Campoli et al. CLINICAL CANCER RESEARCH
- Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
- (2009) B. Li et al. CLINICAL CANCER RESEARCH
- Paclitaxel and immune system
- (2009) Aqeel Javeed et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Risk of additional cancers in untreated and treated hairy cell leukemia patients
- (2009) Constantin A Dasanu et al. EXPERT OPINION ON PHARMACOTHERAPY
- Plasticity of T-cell phenotype and function: the T helper type 17 example
- (2009) Ariana Peck et al. IMMUNOLOGY
- Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice
- (2009) Hanh K. Le et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
- (2009) Leisha A. Emens et al. JOURNAL OF CLINICAL ONCOLOGY
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism
- (2009) G. V. Shurin et al. JOURNAL OF IMMUNOLOGY
- Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C)
- (2009) M. L. Salem et al. JOURNAL OF IMMUNOLOGY
- Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells
- (2009) E. M. Hanson et al. JOURNAL OF IMMUNOLOGY
- Administration of Cyclophosphamide Changes the Immune Profile of Tumor-bearing Mice
- (2009) Pu Liu et al. JOURNAL OF IMMUNOTHERAPY
- Cancer immunoediting and “spontaneous” tumor regression
- (2009) Neel Sengupta et al. PATHOLOGY RESEARCH AND PRACTICE
- Mechanisms of Chemotherapeutic Drug Resistance in Cancer Therapy—A Quick Review
- (2009) Fu-Shing Liu Taiwanese Journal of Obstetrics & Gynecology
- Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
- (2008) K. Movahedi et al. BLOOD
- Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells
- (2008) Yu Liu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells
- (2008) P. Serafini et al. CANCER RESEARCH
- Effective Depletion of Regulatory T Cells Allows the Recruitment of Mesothelin-Specific CD8+T Cells to the Antitumor Immune Response Against a Mesothelin-Expressing Mouse Pancreatic Adenocarcinoma
- (2008) Ihid C. Leao et al. CTS-Clinical and Translational Science
- Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients
- (2008) Paola Nisticò et al. INTERNATIONAL JOURNAL OF CANCER
- Combining an EGF-based Cancer Vaccine With Chemotherapy in Advanced Nonsmall Cell Lung Cancer
- (2008) Elia Neninger et al. JOURNAL OF IMMUNOTHERAPY
- Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression
- (2008) S. Peter Bak et al. MOLECULAR IMMUNOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started